SA PRO
Free Account
Ventyx Biosciences, Inc.VTYXNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
11 analysts·Moderate coverage
36%
Rating Distribution
Strong Buy
00%
Buy
436%
Hold
764%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Price is near analyst consensus — limited near-term upside expected.

Bear Case
$14.00
+0%
Consensus
$14.00
+0%
Bull Case
$14.00
+0%
Price Range11 analysts
Low
Consensus
High
$14.00
$14.00
Current Target
Current Price
$13.96
Upside to Target
$0.04

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.71(6 analysts)
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+75.02%
EPS—
FY2028
Rev+698.20%
EPS—
FY2029
Rev+21.29%
EPS—

Earnings Surprises

Beat rate:50%(6/12 quarters)
Avg surprise:+5.2%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 8, 2026Piper Sandler
Ventyx Biosciences downgraded to Neutral from Overweight at Piper Sandler
Target:$14.00
+1.6%from $13.79
Jan 8, 2026H.C. Wainwright
Ventyx Biosciences downgraded to Neutral from Buy at H.C. Wainwright
Target:$14.00
+2.0%from $13.73
Jan 8, 2026UBS
Ventyx Biosciences downgraded to Neutral from Buy at UBS
Target:$14.00
+2.0%from $13.73
Jan 8, 2026Canaccord Genuity
Ventyx Biosciences downgraded to Hold from Buy at Canaccord
Target:$14.00
+2.0%from $13.73
Jan 7, 2026UBS
Ventyx Biosciences initiated with a Buy at UBS
Target:$20.00
+45.1%from $13.78
Nov 5, 2025H.C. Wainwright
Ventyx Biosciences upgraded to Buy from Neutral at H.C. Wainwright
Target:$18.00
+122.5%from $8.09
Oct 27, 2025Oppenheimer
Ventyx Biosciences price target raised to $14 from $9 at Oppenheimer
Target:$14.00
+136.2%from $5.93
Jun 13, 2024H.C. Wainwright
H.C. Wainwright Maintains Ventyx Biosciences (VTYX) at Neutral, NT-0796 results have "limited significance"
Target:$6.00
+101.3%from $2.98
Jun 6, 2024Oppenheimer
Ventyx Biosciences Inc (VTYX) PT Lowered to $10 at Oppenheimer
Target:$10.00
+89.4%from $5.28
Mar 12, 2024Wells Fargo
Wells Fargo Upgrades Ventyx Biosciences Inc (VTYX) to Overweight, 'We're Taking a Swing on VTYX's NLRP3 Programs'
Target:$16.00
+90.0%from $8.42
Mar 12, 2024Oppenheimer
Oppenheimer Upgrades Ventyx Biosciences Inc (VTYX) to Outperform, 'Narrows Focus to the NLRP3 Programs'
Target:$12.00
+42.5%from $8.42
Dec 19, 2022Goldman Sachs
Goldman Sachs Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $50
Target:$50.00
+53.2%from $32.64
Nov 17, 2022Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
Target:$45.00
+77.0%from $25.43
Sep 13, 2022Jefferies
Ventyx Biosciences (VTYX) Stock: Why It Surged 64.98%
Target:$60.00
+57.4%from $38.11
May 12, 2022Piper Sandler
Ventyx Biosciences 'top pick' heading into data-rich Q3, says Piper Sandler
Target:$50.00
+244.1%from $14.53

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance